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PURPOSE: The aim of this study was to evaluate the degree of metastatic bone pain palliation and medullar toxicity
associated with samarium-153-EDTMP treatment.
METHODS: Seventy-three patients with metastatic bone pain having previously undergone therapy with samarium-
153-EDTMP (1 mCi/kg) were retrospectively evaluated. Routine follow-up included pain evaluation and blood counts for
2 months after treatment. Pain was evaluated using a subjective scale (from 0 to 10) before and for 8 weeks after the
treatment. Blood counts were obtained before treatment and once a week for 2 months during follow-up. Dosimetry, based
upon the urinary excretion of the isotope, was estimated in 41 individuals, and the resulting radiation absorbed doses were
correlated with hematological data.
RESULTS: Reduction in pain scores of 75% to 100% was obtained in 36 patients (49%), with a decrease of 50% to
75%, 25% to 50%, and 0% to 25% in, respectively, 20 (27%), 10 (14%), and 7 (10%) patients. There was no significant
relationship between the pain response and location of the primary tumor (breast or prostate cancer). Mild to moderate
myelosuppression was noted in 75.3% of patients, usually with hematological recovery at 8 weeks. The mean bone marrow
dose was 347 ± 65 cGy, and only a weak correlation was found between absorbed dose and myelosuppression (Pearson
coefficient = .4).
CONCLUSIONS: Samarium-153-EDTMP is a valuable method for metastatic bone pain palliation. A mild to moderate
and transitory myelosuppression is the main toxicity observed after samarium therapy, showing a weak correlation with
dosimetric measures.
KEYWORDS: Samarium. Pain. Scintigraphy. Palliative. Care. Neoplasm. Metastasis.
Bone metastases are common in
the progression of various tumors such
as prostate, breast, and lung carcinoma,
and they often entail an occurrence of
progressive pain.1 Control of pain and
its consequences (eg, depression,
movement constraint, and dependence)
are important goals in oncological
treatment requiring a multidisciplinary
approach to the patient.
The use of ionizing radiation is
one of the alternatives for pain treat-
ment, together with the administration
of drugs (eg, anti-inflammatories,
opioids, chemotherapeutic drugs,
receptor blockades, phosphonates) and
surgical interventions. Local radio-
therapy results in a good clinical re-
sponse in approximately 80% of the
cases (complete in 30% to 60%) last-
ing for over 4 months, although with
an effect confined to the irradiated
site.2,3 Hemibody radiotherapy (iso-
lated or sequential) may be used in pa-
tients with widespread metastases, re-
sulting in a complete response in ap-
proximately 20% of the cases, and a
partial one for 50% to 100%. Radia-
tion on wide areas is limited by
hematopoietic, pulmonary, and
gastrointestinal toxicity produced by
the high radiation absorbed dose.2,3
The irradiation of multiple bone
lesions can also be achieved by the in-
travenous administration of beta-emit-
ting isotopes with a high affinity for
322
REV. HOSP. CLÍN. FAC. MED. S. PAULO 59(6):321-328, 2004Retrospective evaluation of bone pain palliation
Sapienza MT et al.
bone metastases. Beta radiation energy
is almost completely delivered to the
specific site of uptake, with a minimal
effect on neighboring tissues. The
main radioisotopes used for palliation
of bone pain due to metastatic malig-
nancies are strontium-89 and samar-
ium-153, with response rates between
60% and 80%.2,4 The isotope most fre-
quently used in Brazil is samarium-
153 due to its wide availability and
low cost (150 dollars per treatment,
compared to approximately 2,000 dol-
lars for strontium-89).
S a m a r i u m - 1 5 3 – l a b e l e d
ethylenediaminetet ramethylene
phosphonic acid (153Sm-EDTMP) is re-
tained in the mineral phase of bone,
probably by adsorption to hydroxya-
patite crystals, similarly to the mecha-
nism involved in the uptake of
radiopharmaceuticals used in bone
scans. Treatment with 153Sm-EDTMP
was first described in 1989,5 and it was
first approved for clinical use in the
USA in 1997. In Brazil, samarium-153
is produced by the Institute for Ener-
getic and Nuclear Researches (IPEN -
Instituto de Pesquisas Energéticas e
Nucleares – São Paulo) and has been
used clinically since 1995, initially as
part of an international program coor-
dinated by the International Atomic
Energy Agency (IAEA – Vienna), and
later as a routine procedure covered by
the Brazilian healthcare system (SUS-
Sistema Único de Saúde).
Clinical response to treatment with
153Sm-EDTMP (pain reduction) is de-
scribed in 55% to 88% of the cases,
beginning 5 to 7 days after injection,
and lasting for 2 to 17 weeks.6,7,8 The
shorter half-life of samarium-153 com-
pared to strontium-89 (2 versus 50
days) may be related to the smaller in-
terval for the response start (5 to 7 ver-
sus 10 to 20 days) and to its shorter
duration (2 to 3 versus 3 to 4 months).
Bone marrow toxicity is the main
adverse reaction observed after treat-
ment with samarium-153, generally
occurring in a mild to moderate de-
gree, reaching a peak between 3 and 4
weeks and subsiding after 6 to 8
weeks. Grade III toxicity is described
in approximately 10% of the patients
treated with doses of 1 mCi/kg,9,10,11,12
and grade IV toxicity occurs in less
than 1% of cases. In addition to beta-
particle emission (energy = 810 keV),
samarium-153 emits gamma radiation
(energy = 103 keV), which may be
used for biodistribution and dosimetric
measures. A bone uptake of 55% to
75% of the injected dose is confirmed
in these measurements,13,14 resulting in
a radiation absorbed dose of approxi-
mately 7 cGy/mCi in normal bone and
42 cGy/mCi in osteoblastic bone le-
sions.2
To the best of our knowledge,
clinical results of the treatment with
153Sm-EDTMP in Brazil have not yet
been described, even though there is
almost one decade of experience.
The objectives of the current study
were:
1- to evaluate the clinical response
(pain intensity variation) and the
marrow toxicity after treatment
with 153Sm-EDTMP;
2- to correlate the degree of marrow
toxicity with the radiation ab-
sorbed dose of the bone marrow.
METHODS
Patients
Medical records of 178 patients
were retrospectively reviewed. Patients
had been sent for treatment with 153Sm-
EDTMP to the Nuclear Medicine Serv-
ice of our Institute between 1995 and
2002. Patient records were considered
adequate if there were data for at least
75% of the routine clinical and labo-
ratory fields (daily pain evaluation
and weekly blood counts for 8 weeks).
As part of the treatment planning,
all patients had a consultation with a
nuclear medicine physician to confirm
the indications and to exclude even-
tual contraindications to the treatment,
and all signed an informed consent.
Indications for treatment were pain due
to bone metastases requiring increas-
ing analgesic doses, clinically uncon-
trolled pain, or recurring pain in a pre-
viously irradiated site. An additional
criterion was the detection of multiple
osteoblastic lesions in a recent bone
scan (less than a 3-month interval)
showing moderate to outstanding ra-
diopharmaceutical uptake. Treatment
was contraindicated for patients with
one or more of the following criteria:
severely disabled patients, leukopenia
(<2,500/mm3) or thrombocytopenia
(<100,000 mm3) in a recent blood test
(less than 1 week), progressive drop of
the platelet count, less than 1 month
interval from chemotherapy or 2
months from radiotherapy involving
more than 20% of the bone marrow, or
pregnancy. Patients with pain due to a
suspected pathological fracture, nerve
compression, or soft tissue invasion
were directed to complementary inves-
tigation and treatment with other
modalities because treatment with
153Sm-EDTMP was not indicated.
Treatment and follow-up
Pain intensity before treatment was
subjectively assessed by the patients
themselves using a 0-to-10 scale (0 =
no pain, 10 = maximum pain). Anal-
gesics used, their doses, and their use
intervals were also recorded. Outpa-
tient treatment was performed by the
intravenous administration of 153Sm-
EDTMP (IPEN - São Paulo, Brazil)
through an upper limb access.
Routine follow-up included clinical
and laboratory surveillance. Clinical
surveillance consisted of daily pain in-
tensity reporting for 8 weeks. The clini-
cal response was appraised by compar-
ing weekly pain intensity averages with
the pretreatment value. Patients were
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grouped according to their pain inten-
sity drop, that is, 0% to 25%, 25.1% to
50%, 50.1% to 75%, and 75.1% to
100%. Pain flare, a transitory worsen-
ing of pain after treatment,4,15 was de-
fined by a greater-than-2-point increase
in the pain scale within 5 days after the
administration of 153Sm-EDTMP.
Blood counts were also obtained
weekly during the same 8-week period,
and the corresponding leukocyte
count, platelet count, and hemoglobin
concentration were recorded. Absolute
and percent variations of these param-
eters were calculated compared to ba-
sal values (obtained at 1 week or less
pretreatment). Medullary toxicity,
based on the lowest leukocyte and
platelet values observed during follow-
up, was classified in accordance with
the National Cancer Institute Com-
mon Toxicity Criteria - Version 1.
Dosimetric calculations
After the administration of 153Sm-
EDTMP, 41 of the 73 patients under-
went dosimetric calculation. Urinary
excretion of samarium-153 by these 41
patients was measured hourly for 6
hours, and an activity retention curve
was drawn. Previously described mod-
els16,17 were used to determine the ac-
tivity distribution in the different in-
tervals. These data were used to calcu-
late the accrued activity integral in the
cortical and trabecular bone using
equation 1, where A = accrued activ-
ity, A(t) = retained activity in each
structure in the various times, … = in-
termediate terms between 1 and 24
hours, and λ = the samarium-153 dis-
integration constant.
The radiation absorbed dose of the
hematopoietic marrow resulting from
the emission of beta particles from the
isotope retained in the cortical and in
the trabecular bone was calculated us-
ing equation 2, where S = radiation ab-
sorbed dose per accrued activity unit,
cor = cortical bone, trab = trabecular
bone. The marrow radiation absorbed
dose was corrected according to the
patient’s weight, based on the 70 kg
and 170 cm reference-man (ICRP 23).
Statistical evaluation
Mean and standard deviation of the
initial pain intensity, clinical response,
and medullary toxicity were estimated
for the whole group of patients. The
Student t test was used to compare pain
intensity prior to and at the end of the
eighth week after treatment (1-tailed
paired t test, P <.05), as well as to com-
pare the treatment response between
patients with primary breast or prostate
cancer (2-tailed t test, P <.05). The re-
lationship between the decrease in
platelet and leukocyte counts and the
radiation absorbed dose of the bone
marrow was evaluated using Pearson’s
linear correlation coefficient.
RESULTS
Medical records were considered
appropriate for analysis in 73 patients
(37 males and 36 females; age range,
31 to 89 years, mean ± SD, 60 ± 15
years) who had the following as a pri-
mary tumor: prostate carcinoma (n =
36), breast carcinoma (n = 29), lung
carcinoma (n = 5), colorectal carci-
noma (n = 1), parathyroid carcinoma
(n = 1), or unknown primary tumor (n
= 1). Patient records were considered
inappropriate for analysis in the re-
maining 105 patients (62 followed up
at Hospital das Clínicas de São Paulo;
43 at other institutions).
The mean value for pain intensity
dropped from 7.1 ± 2.8 to 3.4 ± 2.8 in
the first 2 weeks after treatment, hold-
ing at 3.0 ± 2.3 in the eighth week af-
ter treatment (Figure 1). Pain intensity
in the eighth week after treatment was
significantly lower than pain before
treatment (P <.001).
During follow-up, a maximum pain
intensity reduction of 5.83 ± 2.13
points with respect to the initial value
(percent reduction: 70.5% ± 27.7%)
was observed. A 75% to 100% pain re-
duction occurred in 36 patients (49%),
and a 50% to 75% reduction occurred
in 20 cases (27%). Pain reduction was
less than 50% in the other cases (25%
to 50% in 10 cases and 0% to 25% in
7 cases) (Figure 2). No statistical dif-
ference was observed in pain intensity
reduction either in absolute scale (P =
.983) or in percent scale (P = .069)
when patients with prostate and breast
carcinoma were compared.
In 7 patients, a transitory worsen-
ing of pain was observed during the
first week after treatment, with a mean
increase of 3.76 ± 0.78 in the pain
scale. The response subsequently ob-
served in this subset of patients was
similar to that seen in the others (re-
duction of 70% ± 35% compared to
the initial pain intensity).
Pretreatment blood count values
were as follows: hemoglobin = 11.5 ±
2.0 g/dL, leukocytes = 6,820 ± 3,480/
mm3, and platelets = 237,200 ±
95,000/mm3. 75.3% of the patients ex-
perienced leukopenia and/or thrombo-
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the patients had leukopenia (grade I
toxicity = 26.0%, grade II = 28.8%,
grade III = 16.4%); and 53.4% had
thrombocytopenia (grade I toxicity =
15.1%, grade II = 17.8%, grade III =
19.2%, grade IV = 1.4%) (Figure 3).
Leukopenia and thrombocytopenia
occurred simultaneously in 36 cases,
while isolated leukopenia or thrombo-
cytopenia occurred, respectively, in 16
and 3 patients. Platelet count variation
was only weakly correlated with
leukocyte count variation (Pearson’s
coefficient r = .41). The correlation be-
tween the minimum and basal values
was also low for both leukocyte and
platelet counts (r =.30 and .62).
The platelet and leukocyte nadir
occurred between 4 and 5 weeks after
treatment, with recovery to 78% of ba-
sal leukocyte values (average ± SD =
4,910 ± 1,830/mm3) and 88% of basal
platelet values (187,700 ± 81,500/
mm3) at the end of the eighth week
(Figure 4). Persistent leukopenia was
still present between the seventh and
the eighth weeks in 26% of the cases
(4% had between 1,000 and 2,000
leukocytes/mm3, 8% had between
2,000 and 3,000 leukocytes/mm3, and
14% had between 3,000 and 4,000
leukocytes/mm3). Thrombocytopenia
was still present in 16% of cases (4%
had between 25 and 50 thousand
platelets/mm3, 4% had between 50 and
75 thousand platelets/mm3, and 8%
had between 75 and 100 thousand
platelets/mm3).
 The radiation absorbed dose of
bone marrow varied from 195 to 468
cGy (mean ± SD = 347 ± 65 cGy) in
the 41 patients. The radiation ab-
sorbed dose had a low correlation with
the maximum decrease in leukocyte
counts during follow-up (Pearson’s co-
efficient r = .40), as well as with the
maximum drop in platelet counts
(Pearson’s coefficient r = .48).
DISCUSSION
Intravenous injection of strontium-
89 and samarium-153 for the treatment
of pain due to osteoblastic metastasis
has been widely described in the lit-
erature, mainly for patients with hor-
mone-refractory prostate carcinoma or
with breast carcinoma, with reported
responses between 55% and 83% of
patients.1,5,6,7,15,18,19-22 The clinical re-
sponse observed in this study was
similar to that described in literature,
the pain having been reduced to less
than 50% of basal levels in 76% of
cases, with no distinction as to the pri-
mary tumor (breast or prostate). Pain
improvement after treatment is prob-
ably related to a reduction in both in-
flammatory infiltrate and cytokine re-
lease, together with a change in osteo-
clastic and osteoblastic function. Pain
increase during the first week after
treatment (a phenomenon known as
“pain flare” and probably related to
cytokine release) was observed in 10%
of patients, a value comparable to that
described in the literature.15
Our findings of bone marrow tox-
icity were also similar to those de-
scribed in the literature, with
leukopenia in 71.2% of patients and
thrombocytopenia in 53.4% of our pa-
tients. Concentration of leucocytes and
platelets reached a nadir between 4
and 5 weeks after treatment. There was
a good recovery in blood counts dur-
ing follow-up, reaching 78% of initial
leukocyte count and 88% of initial
Figure 1 - Pain intensity before and for 8 weeks after treatment with 153Sm-EDTMP.
Figure 2 - Percent decrease in pain intensity after treatment with 153Sm-EDTMP.
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platelet count. In addition to the risks
of leukopenia and thrombocytopenia,
long-lasting marrow depression is a
reason for concern because it may
cause difficulty in future treatments
with cytostatic agents. Even though
leukopenia persisted in 26% of pa-
tients and thrombocytopenia in 16%,
it is difficult to determine if medullary
function was permanently jeopardized,
since further improvement in labora-
tory parameters may have occurred af-
ter the 8-week follow-up. On the other
hand, bone marrow infiltration by the
primary disease and the effect of pre-
vious chemotherapy could also con-
tribute to the nonreversion of the med-
ullary depression.
The usual activity for treatment
with samarium-153-EDTMP is 1 mCi/
kg.10,11,23 With this activity, various au-
thors describe the radiation absorbed
dose in the marrow to be between 230
and 590 cGy16,18,21,24 (a range that in-
cludes the results of this study, ie, 347
± 65 cGy). Administration of doses
above 1 mCi/kg seems not to lead to
better pain control,9 even though it re-
sults in higher marrow toxicity.9,12,15,24
Though other studies have shown that
administration of higher activities in-
creases the risk of bone marrow toxic-
ity,9,24,25 the current study did not show
a direct correlation between toxicity
and individual dosimetric measures.
The low correlation observed suggests
that other factors not evaluated in this
study (such as previous chemotherapy,
radiotherapy, and the extent of bone
metastasis) could have reduced the
bone marrow reserve, thus increasing
the radiopharmaceutical toxicity.
Retrospective analysis imposed
several restrictions on the current
study, some of which were due to the
fact that the follow-up file card had
been designed approximately 8 years
ago. We particularly regret that fields
were not included for the clinical find-
ings of medullary toxicity (febrile neu-
tropenia, bleeding, and transfusions)
Figure 3 - a) Number of patients with medullary toxicity after treatment with 153Sm EDTMP
(characterized by thrombocytopenia)*. b) - Number of patients with medullary toxicity after
treatment with 153Sm-EDTMP (characterized by leucopenia)*.
Figure 4 - Blood counts before and for 8 weeks after treatment with 153Sm-EDTMP.
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and for the objective evaluation of
clinical parameters (for instance,
Karnofsky’s index of clinical perform-
ance). The comparison of average
weekly pain intensity with the pretreat-
ment value had the purpose of reduc-
ing the interference of natural oscilla-
tions on pain intensity. Additionally,
it should be noted that the initial pain
score was based on an isolated evalu-
ation; thus, a bias may have occurred
due to a return to the average during
follow-up.
The possibility of a selection bias
must also be considered since it is more
probable that patients with an unsatis-
factory response to treatment would fail
to complete follow-up. Though these
data were not included in the current
study, we observed that patients with
incomplete information were prone to
higher pain intensity in the basal evalu-
ation (8.64 ± 2.0 points) and to a lower
response intensity (average reduction of
4.4 ± 2.7 points).
In addition to the difficulties pecu-
liar to retrospective data collections
and the lack of a control group, this
study also had limitations inherent to
the type of clinical situation evaluated,
including the possible simultaneous or
sequential use of other therapies and
the interference of patients’ activities
according to pain intensity. We consid-
ered patients’ basal situations as a ref-
erence for the evaluation of clinical re-
sponse and of adverse reactions during
follow-up, and it is our experience that
other treatments are generally intro-
duced before the indication for samar-
ium-153-EDTMP. It should be noted
that there was no overlapping of
chemotherapy, introduction of ster-
oids, or hormone therapy in the period
comprising the previous month and
the 2 follow-up months after samar-
ium-153-EDTMP administration—fac-
tors that could interfere in the response
and adverse reactions analysis. There
were analgesic consumption changes
during the follow-up period, with a
tendency towards reduction in the
dose and frequency of use among pa-
tients with a pain reduction higher
than 50%; this suggests that the ob-
served response had effectively origi-
nated from use of samarium-153-
EDTMP. However, analgesic types,
doses, and use intervals were incom-
pletely reported in almost all cases and
therefore could not be included in the
results.
CONCLUSIONS
Treatment with 153Sm-EDTMP re-
sulted in a good clinical response with
a reduction in the subjective appraisal
of pain to less than 50% of the basal
intensity in 76% of the patients.
The main adverse effect observed
during follow-up was a transitory med-
ullary depression to a mild to moder-
ate degree that was only weakly cor-
related with dosimetric measures.
Leukopenia was observed in 71.2% of
the patients and thrombocytopenia in
53.4%; however, most of the patients
had recovered at the end of the eighth
week.
RESUMO
SAPIENZA MT e col. Avaliação retros-
pectiva do tratamento da dor óssea
metastática com Samário-153-
EDTMP. Rev. Hosp. Clín. Fac.
Med. S. Paulo 59(6):321-328,
2004.
OBJETIVO: O presente trabalho
teve por objetivo avaliar o efeito pali-
ativo da dor e a toxicidade medular as-
sociados ao tratamento com Samário-
153-EDTMP em pacientes com metás-
tases ósseas.
MÉTODOS: O estudo foi realiza-
do de forma retrospectiva, a partir do
levantamento de prontuário de 178
pacientes submetidos a tratamento
com 1mCi/kg de 153Sm-EDTMP devi-
do à dor por metástases ósseas. Os
prontuários de 73 pacientes foram con-
siderados adequados para análise dos
parâmetros clínicos (intensidade da
dor) e laboratoriais (hemograma). A in-
tensidade da dor foi avaliada em esca-
la de 0 a 10 pelo próprio paciente, an-
tes e durante 8 semanas após o trata-
mento. Hemograma completo foi rea-
lizado antes do tratamento e a cada se-
mana nas 8 semanas seguintes. Estu-
dos de dosimetria foram realizados em
41 dos 73 pacientes, baseados na
excreção urinária e retenção do radio-
isótopo, sendo a dose de radiação ab-
sorvida correlacionada à toxicidade
medular.
RESULTADOS: Redução impor-
tante na intensidade da dor (diminui-
ção de 75 a 100% do basal) foi cons-
tatada em 36 pacientes (49%), com re-
dução de 50-75%, 25-50% e 0-25%
em, respectivamente, 20 (27%), 10
(14%) e 7 (10%) casos. Não se obser-
vou variação significativa da resposta
entre os pacientes com tumor primário
de mama (n=29) ou de próstata (n=36).
Toxicidade medular foi observada em
75,3% dos pacientes (71,2% com
leucopenia e 53,4% com plaque-
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topenia), em geral de grau leve a mo-
derado e com recuperação ao término
da 8o semana. A dose média de medu-
la foi de 347±65 cGy, havendo baixa
correlação entre a dosimetria medular
e a queda da contagem de leucócitos
(coeficiente de correlação linear de
0,40) ou de plaquetas (coeficiente de
correlação linear = 0,48).
CONCLUSÕES: O tratamento
com Samário-153-EDTMP permitiu
um adequado controle da dor por
metástases ósseas, com significativa
redução na intensidade da dor. A
toxicidade medular transitória foi a
principal reação adversa observada,
em geral de grau leve a moderado,
apresentando baixa correlação com as
medidas dosimétricas.
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